Rec-Biotechnology (RecBio), a Chinese developer of genetically engineered vaccines, has secured about 1 billion yuan ($156.3 million) in a Series C round of financing jointly led by Singapore state investor Temasek Holdings and Hong Kong-based asset manager Lake Bleu Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
